Form 4: ResMed Director Peter Farrell Sells 2,000 Shares Under 10b5-1 Plan

ResMed director Peter Farrell sold 2,000 shares of common stock at $242.25 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of ResMed Common Stock on May 7, 2025.
• The sale was executed at a price of $242.25 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on May 28, 2024.
• Following the transaction, Farrell directly owns 71,218 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.

Industry Context

Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any inside information. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are generally less informative.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information.
• Companies like Medtronic and Philips also see regular insider trading activity, often executed through similar pre-arranged plans.
• The volume of shares sold by Farrell is relatively small compared to the total outstanding shares of ResMed, suggesting it's unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

ResMed, RMD, Peter Farrell, stock sale, Form 4, 10b5-1 plan, director, insider trading